Preoperative staging, prognostic factors, and outcome for extremity rhabdomyosarcoma: a preliminary report from the Intergroup Rhabdomyosarcoma Study IV (1991-1997). 2000

H L Neville, and R J Andrassy, and T E Lobe, and C E Bagwell, and J R Anderson, and R B Womer, and W M Crist, and E S Wiener
IRS Group of the Children's Cancer Group and the Pediatric Oncology Group, Rochester, MN 55905-0001, USA.

BACKGROUND During the fourth Intergroup Rhabdomyosarcoma (RMS) Study (IRS IV, 1991-97), a preoperative staging system was evaluated prospectively for the first time. The authors evaluated this staging system and the role of surgery in extremity RMS in contemporary multimodal therapy. METHODS A total of 139 patients (71 girls; median age, 6 years) were entered in IRS IV with extremity-site RMS. Stage was assigned by the IRSG Preoperative Staging System. Postsurgical group was determined by tumor status after initial surgical intervention. Multivariate analysis was performed using all pretreatment factors that were significant by univariate analysis, including clinical Group (i.e., I through IV), tumor invasiveness (T1,T2), nodal status (N0,N1), and tumor size (< or > or =5 cm). Failure-free survival rates (FFS) and survival rates were estimated using the Kaplan and Meier method. RESULTS Preoperative staging and clinical group distribution were as follows: Stage 2, n = 34; Stage 3, n = 73; Stage 4, n = 32; Group I, n = 31; Group II, n = 21; Group III, n = 54; Group IV, n = 33. Three-year FFS was 55%, and the overall survival rate was 70%. Eighty-seven patients had either unresectable, gross residual disease (Group III) or metastases (Group IV). FFS was significantly worse for these patients with advanced disease, compared with that for patients with complete resection or with only microscopic residual tumor (i.e., Group I or II; Group I, 3-year FFS, 91%; Group II, 72%; Group III, 50%; Group IV, 23%; P<.001). Lymph nodes were evaluated surgically in 76 patients with positive results in 38. Clinically, 13 additional patients had nodal disease. Both stage and group were highly predictive of outcome and were highly correlated. By multivariate analysis, none of the other variables were predictors of FFS. CONCLUSIONS This review confirms the utility of pretreatment staging for stratification of patients with extremity RMS with widely different risks of relapse, thereby paving the way for development of risk-based therapy. Group (operative staging) remains the most important predictor of FFS, emphasizing the importance of complete gross resection at initial surgical intervention, when feasible without loss of limb function. The high incidence of nodal disease in the patients who had lymph node biopsy confirms the need for surgical evaluation of lymph nodes to ensure accurate staging in children with extremity rhabdomyosarcoma.

UI MeSH Term Description Entries
D008297 Male Males
D009361 Neoplasm Invasiveness Ability of neoplasms to infiltrate and actively destroy surrounding tissue. Invasiveness, Neoplasm,Neoplasm Invasion,Invasion, Neoplasm
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005121 Extremities The farthest or outermost projections of the body, such as the HAND and FOOT. Limbs,Extremity,Limb
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012208 Rhabdomyosarcoma A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9) Rhabdomyosarcomas

Related Publications

H L Neville, and R J Andrassy, and T E Lobe, and C E Bagwell, and J R Anderson, and R B Womer, and W M Crist, and E S Wiener
June 2004, Pediatric blood & cancer,
H L Neville, and R J Andrassy, and T E Lobe, and C E Bagwell, and J R Anderson, and R B Womer, and W M Crist, and E S Wiener
January 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
H L Neville, and R J Andrassy, and T E Lobe, and C E Bagwell, and J R Anderson, and R B Womer, and W M Crist, and E S Wiener
January 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
H L Neville, and R J Andrassy, and T E Lobe, and C E Bagwell, and J R Anderson, and R B Womer, and W M Crist, and E S Wiener
January 1996, Journal of pediatric surgery,
H L Neville, and R J Andrassy, and T E Lobe, and C E Bagwell, and J R Anderson, and R B Womer, and W M Crist, and E S Wiener
January 1982, Cancer,
H L Neville, and R J Andrassy, and T E Lobe, and C E Bagwell, and J R Anderson, and R B Womer, and W M Crist, and E S Wiener
November 1977, Cancer,
H L Neville, and R J Andrassy, and T E Lobe, and C E Bagwell, and J R Anderson, and R B Womer, and W M Crist, and E S Wiener
May 2004, The Journal of pediatrics,
H L Neville, and R J Andrassy, and T E Lobe, and C E Bagwell, and J R Anderson, and R B Womer, and W M Crist, and E S Wiener
March 2003, Journal of pediatric surgery,
H L Neville, and R J Andrassy, and T E Lobe, and C E Bagwell, and J R Anderson, and R B Womer, and W M Crist, and E S Wiener
July 1995, Journal of pediatric surgery,
H L Neville, and R J Andrassy, and T E Lobe, and C E Bagwell, and J R Anderson, and R B Womer, and W M Crist, and E S Wiener
February 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Copied contents to your clipboard!